Results 41 to 50 of about 7,431,159 (264)

Protein-Ligand Interactions and Drug Design [PDF]

, 2021
This detailed book collects modern and established computer-based methods aimed at addressing the drug discovery challenge from disparate perspectives by exploiting information on ligand-protein recognition.
Ballante, Flavio,
core   +1 more source

The impact of CYP2C19 genotype on phenoconversion by concomitant medication

Frontiers in Pharmacology, 2023
Introduction: Pharmacogenetics-informed drug prescribing is increasingly applied in clinical practice. Typically, drug metabolizing phenotypes are determined based on genetic test results, whereupon dosage or drugs are adjusted.
Laura M. de Jong, Soukayna Boussallami, Elena Sánchez-López, Martin Giera, Maarten E. Tushuizen, Menno Hoekstra, Lukas J. A. C. Hawinkels, Robert Rissmann, Robert Rissmann, Robert Rissmann, Jesse J. Swen, Martijn L. Manson   +11 more
doaj   +1 more source

Prediction of Drug–Drug–Gene Interaction Scenarios of (E)-Clomiphene and Its Metabolites Using Physiologically Based Pharmacokinetic Modeling

Pharmaceutics, 2022
Clomiphene, a selective estrogen receptor modulator (SERM), has been used for the treatment of anovulation for more than 50 years. However, since (E)-clomiphene ((E)-Clom) and its metabolites are eliminated primarily via Cytochrome P450 (CYP) 2D6 and ...
Christina Kovar, Lukas Kovar, Simeon Rüdesheim, Dominik Selzer, Boian Ganchev, Patrick Kröner, Svitlana Igel, Reinhold Kerb, Elke Schaeffeler, Thomas E. Mürdter, Matthias Schwab, Thorsten Lehr   +11 more
doaj   +1 more source

Comparison of Multidrug Use in the General Population and among Persons with Diabetes in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines

Pharmaceuticals, 2021
Background: This study measures the use of drugs within the therapeutic areas of antithrombotic agents (B01), the cardiovascular system (C), analgesics (N02), psycholeptics (N05), and psychoanaleptics (N06) among the general population (GP) in comparison
Niels Westergaard, Lise Tarnow, Charlotte Vermehren   +2 more
doaj   +1 more source

The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients

Pharmacy, 2023
Patients with chronic kidney disease (CKD) stage 3–5 are polypharmacy patients. Many of these drugs are metabolized by cytochrome P450 (CYP450) and CYP450. Genetic polymorphism is well known to result in altered drug metabolism capacity.
Catharina H. M. Kerskes, Carien J. M. E. van den Eijnde, Albert-Jan L. H. J. Aarnoudse, René J. E. Grouls, Birgit A. L. M. Deiman, Maarten J. Deenen   +5 more
doaj   +1 more source

Discovering Drug-Drug Interactions Using Association Rule Mining from Electronic Health Records [PDF]

, 2023
In this paper, we propose utilising Electronic Health Records (EHR) to discover previously unknown drug-drug interactions (DDI) that may result in high rates of hospital readmissions.
Chahed, S., Getting, S., Dwek, M., Chaussalet, T., Nazyrova, N.   +4 more
core   +1 more source

DeSIDE-DDI: interpretable prediction of drug-drug interactions using drug-induced gene expressions

Journal of Cheminformatics, 2022
Adverse drug-drug interaction (DDI) is a major concern to polypharmacy due to its unexpected adverse side effects and must be identified at an early stage of drug discovery and development.
Eunyoung Kim, Hojung Nam
doaj   +1 more source

Uncovering Key Metabolic Determinants of the Drug Interactions Between Trimethoprim and Erythromycin in Escherichia coli

Frontiers in Microbiology, 2021
Understanding interactions between antibiotics used in combination is an important theme in microbiology. Using the interactions between the antifolate drug trimethoprim and the ribosome-targeting antibiotic erythromycin in Escherichia coli as a model ...
Qin Qi, Qin Qi, S. Andreas Angermayr, Tobias Bollenbach, Tobias Bollenbach   +4 more
doaj   +1 more source

Drug-drug interactions in the hospital [PDF]

, 2007
Introduction Drug interaction screening programs are an important tool to check prescriptions of multiple drugs for potential drug-drug interactions (pDDIs). Several programs are available on the market.
Vonbach, Priska
core   +1 more source

Hyponatremic Cognitive Dysfunction Resulting from Drug-Drug-Gene Interaction between Sertraline and Cannabidiol in an Intermediate CYP2C19 Metabolizer Patient

INNOVATIONS in Pharmacy, 2022
Background: Pharmacogenomics (PGx) can provide more precision in determining causation of adverse drug reactions (ADRs) from drug-drug-gene interaction clinical application.
Jade Nanan, Sheena Crosby, Michael J. Schuh   +2 more
doaj   +1 more source